Low frequency of HER2 amplification and overexpression in early onset gastric cancer

Cellular Oncology

Volumn 34, Issue 2, 2011, Pages 89-95

  Moelans, Cathy B ^a   Milne, Anya N ^a   Morsink, Folkert H ^a   Offerhaus, G Johan A ^a   Van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Gastric cancer; HER2; Immunohistochemistry; In situ hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TISSUE MICROARRAY; AGE; CLINICAL TRIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; STOMACH TUMOR;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 79960906419     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-011-0021-0     Document Type: Article

References (45)

1. Y. Bang, H. Chung, J. Xu, F. Lordick, A. Sawaki, N. Al-Sakaff et al., Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J. Clin. Oncol. 27, 4556 (2009)
2. Y.J. Bang, C.E. Van, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment ofHER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010)
3. J.D. Barros-Silva, D. Leitao, L. Afonso, J. Vieira, M. nis-Ribeiro, M. Fragoso et al., Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 100, 487-493 (2009)
4. M.Bilous, R.Y.Osamura, J.Ruschoff, d.van, V, W.Hanna, F. Penault-Llorca et al., HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 41, 304-305 (2010)
5. A. Brufsky, Trastuzumab-based therapy for patients with HER2-positive breast cancer: From early scientific development to foundation of care. Am. J. Clin. Oncol. 33, 186-195 (2010)
6. R. Carvalho, A.N.Milne,M. Polak,W.E. Corver, G.J. Offerhaus, M. A. Weterman, Exclusion of RUNX3 as a tumour-suppressor gene in early-onset gastric carcinomas. Oncogene 24, 8252-8258 (2005) (Pubitemid 43250917)
7. R. Carvalho, A.N. Milne, B.P. van Rees, E. Caspers, L. Cirnes, C. Figueiredo et al., Early-onset gastric carcinomas display molecular characteristics distinct from gastric carcinomas occurring at a later age. J Pathol 204, 75-83 (2004) (Pubitemid 39214484)
8. P. Correa, Y.H. Shiao, Phenotypic and genotypic events in gafstric carcinogenesis. Cancer Res. 54, 1941s-1943s (1994) (Pubitemid 24132151)
9. A.Dobi, G.Kelemen, L.Kaizer, R.Weiczner, L.Thurzo, and Z.Kahan, Breast Cancer under 40 Years of Age: Increasing Number andWorse Prognosis, Pathol Oncol Res (2010), doi:10.1007/s12253-010-9305-3
10. H. Furukawa, T. Iwanaga, S. Imaoka, M. Hiratsuka, I. Fukuda, T. Kabuto et al., Multifocal gastric cancer in patients younger than 50 years of age. Eur. Surg. Res. 21, 313-318 (1989) (Pubitemid 20179621)
11. H. Grabsch, S. Sivakumar, S. Gray, H.E. Gabbert, W. Muller, HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value -conclusions from 924 cases of two independent series. Cell. Oncol. 32, 57-65 (2010)
12. C. Gravalos, A. Jimeno, HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann. Oncol. 19, 1523-1529 (2008)
13. S. Guiu, M. Gauthier, B. Coudert, F. Bonnetain, L. Favier, S. Ladoire et al., Pathological complete response and survival according to the level of HER-2 amplification after trastuzumabbased neoadjuvant therapy for breast cancer. Br. J. Cancer 103, 1335-1342 (2010)
14. K. Hede, Gastric cancer: Trastuzumab trial results spur search for other targets. J. Natl Cancer Inst. 101, 1306-1307 (2009)
15. M. Hofmann, O. Stoss, D. Shi, R. Buttner, V.W. d.van Kim et al., Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology 52, 797-805 (2008) (Pubitemid 351724903)
16. J.T. Jorgensen, Targeted HER2 treatment in advanced gastric cancer. Oncology 78, 26-33 (2010)
17. P.A. Kaufman, G. Broadwater, K. Lezon-Geyda, CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2-metastatic breast cancer (MBC). J. Clin. Oncol. 25(Suppl 18), 1009 (2007)
18. D.Y. Kim, S.Y. Ryu, Y.J. Kim, S.K. Kim, Clinicopathological characteristics of gastric carcinoma in young patients. Langenbecks Arch. Surg. 388, 245-249 (2003) (Pubitemid 37210352)
19. A. Kokkola, P. Sipponen, Gastric carcinoma in young adults. Hepatogastroenterology 48, 1552-1555 (2001) (Pubitemid 34003473)
20. P. Lauren, The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64, 31- 49 (1965)
21. S. Lim, H.S. Lee, H.S. Kim, Y.I. Kim, W.H. Kim, Alteration of Ecadherin-mediated adhesion protein is common, but microsatellite instability is uncommon in young age gastric cancers. Histopathology 42, 128-136 (2003) (Pubitemid 36237844)
22. M. Maeta, H. Yamashiro, A. Oka, S. Tsujitani, M. Ikeguchi, N. Kaibara, Gastric cancer in the young, with special reference to 14 pregnancy-associated cases: Analysis based on 2, 325 consecutive cases of gastric cancer. J. Surg. Oncol. 58, 191-195 (1995)
23. A.H. Marx, L. Tharun, J. Muth, A.M. Dancau, R. Simon, E. Yekebas et al., HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 40, 769-777 (2009)
24. P.J. Matley, D.M. Dent, M.V. Madden, S.K. Price, Gastric carcinoma in young adults. Ann. Surg. 208, 593-596 (1988) (Pubitemid 18267700)
25. A.N. Milne, F. Carneiro, C. O'Morain, G.J. Offerhaus, Nature meets nurture: Molecular genetics of gastric cancer. Hum. Genet. 126, 615-628 (2009)
26. A.N. Milne, R. Carvalho, M. Jansen, E.K. Kranenbarg, C.J. van de Velde, F.M. Morsink et al., Cyclin E low molecular weight isoforms occur commonly in early-onset gastric cancer and independently predict survival. J Clin Pathol 61, 311-316 (2008) (Pubitemid 351354236)
27. A.N. Milne, R. Carvalho, F.M. Morsink, A.R. Musler, W.W. de Leng, A. Ristimaki et al., Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol 19, 564-572 (2006)
28. A.N. Milne, R. Leguit, W.E. Corver, F.H. Morsink, M. Polak, W. W. de Leng et al., Loss of CDC4/FBXW7 in gastric carinoma. Cell Oncol 32, 347-359 (2010)
29. A.N. Milne, R. Sitarz, R. Carvalho, F. Carneiro, G.J. Offerhaus, Early onset gastric cancer: On the road to unraveling gastric carcinogenesis. Curr. Mol. Med. 7, 15-28 (2007) (Pubitemid 46322276)
30. S. Paik, C. Kim, N.Wolmark, HER2 status and benefit from adjuvant trastuzumab in breast cancer. N. Engl. J.Med. 358, 1409-1411 (2008) (Pubitemid 351468442)
31. D.I. Park, J.W. Yun, J.H. Park, S.J. Oh, H.J. Kim, Y.K. Cho et al., HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig. Dis. Sci. 51, 1371-1379 (2006) (Pubitemid 44315804)
32. J.C. Park, Y.C. Lee, J.H. Kim, Y.J. Kim, S.K. Lee, W.J. Hyung et al., Clinicopathological aspects and prognostic value with respect to age: An analysis of 3, 362 consecutive gastric cancer patients. J. Surg. Oncol. 99, 395-401 (2009)
33. D.M. Parkin, F. Bray, J. Ferlay, P. Pisani, Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94, 153-156 (2001) (Pubitemid 32911406)
34. J.Ruschoff, M.Dietel, G.Baretton, S.Arbogast, A.Walch, G. Monges et al., HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 457, 299-307 (2010)
35. R. Santoro, F. Carboni, P. Lepiane, G.M. Ettorre, E. Santoro, Clinicopathological features and prognosis of gastric cancer in young European adults. Br. J. Surg. 94, 737-742 (2007) (Pubitemid 46910068)
36. R. Sitarz, R.J. Leguit, W.W. de Leng, F.H. Morsink, W.P. Polkowski, R. Maciejewski et al., Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not earlyonset gastric cancer cell lines. Cell Oncol 31, 475-485 (2009)
37. B.R. Smith, B.E. Stabile, Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young. Arch. Surg. 144, 506- 510 (2009)
38. T. Takehana, K. Kunitomo, K. Kono, F. Kitahara, H. Iizuka, Y. Matsumoto et al., Status of c-erbB-2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int. J. Cancer 98, 833-837 (2002) (Pubitemid 34286677)
39. M. Tanner, M. Hollmen, T.T. Junttila, A.I. Kapanen, S. Tommola, Y. Soini et al., Amplification of HER-2 in gastric carcinoma: Association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16, 273-278 (2005) (Pubitemid 40309309)
40. C.P.Theuer, V.C.de, G.Keese, S.French, T.Arnell, J.Tolmos et al., Gastric adenocarcinoma in patients 40 years of age or younger, Am J Surg 172 (1996), 473-476
41. S. Uchino, H. Tsuda, K. Maruyama, T. Kinoshita, M. Sasako, T. Saito et al., Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 72, 3179-3184 (1993) (Pubitemid 23356757)
42. E. van Cutsem, Y. Kang,H. Chung, L. Shen, A. Sawaki, F. Lordick et al., Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol. 27, LBA4509 (2009)
43. B. Yan, E.X. Yau, S.S. Bte Omar, C.W. Ong, B. Pang, K.G. Yeoh et al., A study of HER2 gene amplification and protein expression in gastric cancer. J. Clin. Pathol. 63, 839-842 (2010)
44. T. Yano, T. Doi, A. Ohtsu, N. Boku, K. Hashizume, M. Nakanishi et al., Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol. Rep. 15, 65-71 (2006)
45. G.Z. Yu, Y. Chen, J.J. Wang, Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: Their relationship with clinicopathological parameters and prognostic significance. J. Cancer Res. Clin. Oncol. 135, 1331-1339 (2009)